Xie, Tebak, et al. propose that persistent implant stress erodes lineage-defining regulatory programs that preserve cell fate and state, uncoupling cellular compensation from tissue needs and driving regulatory drift, thereby reframing implant failure as a loss of adaptive tissue coordination rather than inflammation alone.

Therapeutic blocking antibodies against TL1A are emerging as one of the most compelling targets in IBD. Preliminary phase 2 studies using TL1A-blocking antibodies have demonstrated some of the highest response rates seen in UC and CD. As the field waits for definitive phase 3 study results, the first of which are expected this summer, mechanistic data continue to expand the biological scope of TL1A in IBD.

Shah et al. review the rapidly evolving landscape of ADCs for solid tumors. The authors evaluate major design components, clinical efficacy of approved agents, and determinants of response and resistance. Finally, they discuss promising innovations and rational combination strategies to enhance therapeutic outcomes.